Eliot M. Lurier has been our Interim Chief Financial Officer since October 2021. Mr. Lurier is currently a consultant with Danforth Advisors, LLC, an advisory firm that he joined in July 2021. Mr. Lurier has over 35 years of experience in the life sciences and healthcare industries. Before joining Danforth, from September 2014 to December 2020, Mr. Lurier was the Chief Financial Officer of the Joslin Diabetes Center, Inc., a preeminent diabetes research, clinical care, and education organization. From April 2008 to September 2014, Mr. Lurier served as the Chief Financial Officer of Interleukin Genetics, Inc., during which time it was a public company. Prior to that, Mr. Lurier held senior level financial positions at several companies, including as Finance and Administration and Chief Financial Officer of NUCRYST Pharmaceuticals (where he assisted in its initial public offering and was responsible for the company’s SEC reporting and the implementation of Sarbanes-Oxley requirements), Chief Financial Officer and Chief Operating Officer of Bridge Pharmaceuticals, Inc., Chief Financial Officer of Admetric Biochem, Inc., and Chief Financial Officer, Treasurer and Vice President of Finance of Ascent Pediatrics, Inc. Mr. Lurier also was an auditor at Coopers and Lybrand in Boston, Massachusetts from 1981 to 1983. Mr. Lurier holds a B.S. in Accounting from Syracuse University and is a Certified Public Accountant in Massachusetts.